- Home
- CLLS
CLLS
Cellectis S.A.
as 10-23-2025 3:54pm EST
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 299.0M | IPO Year: | 2007 |
| Target Price: | $8.00 | AVG Volume (30 days): | 219.2K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $5.48 | Next Earning Date: | 11-03-2025 |
| Revenue: | $63,438,000 | Revenue Growth: | 223.09% |
| Revenue Growth (this year): | -12.05% | Revenue Growth (next year): | 66.76% |
Latest Cellectis S.A. News
CLLS Breaking Stock News: Dive into CLLS Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT Newswires
4 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires
7 days ago
European Equities Traded in the US as American Depositary Receipts Down in Friday Trading, Up for Week
GlobeNewswire
8 days ago
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
MT Newswires
8 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires
8 days ago
Top Premarket Gainers
GlobeNewswire
8 days ago
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
MT Newswires
10 days ago
Allogene Therapeutics Faces Patent Infringement Challenges
Compare CLLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLLS Cellectis S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.